Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBDX
- Development stage
- Preclinical
- Lead developer
- ReBio Technologies
- Administration
- Ophthalmic
01
Overview
RBDX is a discovery-stage pharmaceutical candidate being developed by ReBio Technologies for the treatment of post-operative ocular inflammation. Listed as a research program within the company's ophthalmic pipeline, RBDX is intended to address inflammatory responses following eye surgery. As of early 2024, specific details regarding its chemical structure, molecular target, and modality remain proprietary and have not been disclosed by the developer. The program is part of ReBio's broader focus on ocular oncology and ophthalmology, which often leverages their proprietary SiSu® drug delivery platform for sustained-release applications.
Beyond the preview
Go deeper on RBDX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBDX.